This note is the one to read once the others have done their work and a decision is in front of you. It states plainly what the evidence supports, who it was generated in, and where it stops.
What the study supports. In a twelve-week, single-blind, vehicle-controlled trichoscopy study of forty participants, terminal hair density in the active group rose 33.5% above baseline (p<0.0001), against 7.2% in the vehicle group. Shaft diameter, the anagen-to-telogen ratio, and scalp-barrier measures moved in the same direction. The full design, and its limits, are documented in Note 09.
Who it was measured in. The cohort was selected for reduced density of the diffuse, telogen-effluvium kind: the gradual thinning and increased shedding described in Note 01, not the patterned, receding-hairline loss driven mainly by hormones. If your thinning is diffuse, you resemble the people the figure was measured in. If it is patterned, the study does not speak to your case, and we will not imply that it does.
What it does not support. Forty participants over twelve weeks is a defined measurement, not a population-scale claim. The figure is a group mean; individual response varies around it. And the data describe continued use: the growth phase the actives support is sustained while the protocol is run, and the published number reflects three consecutive four-week cycles, as set out in Note 11. It is not a one-bottle promise.
That is the whole of it. If diffuse density loss is what you are measuring on your own scalp, the protocol these notes describe is the one that was studied. The evidence is on the table; the decision is yours.